Sirnaomics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sirnaomics sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
Sirnaomics: 11 sponsored US clinical trials, 1 recruiting.
Sirnaomics sponsors 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cutaneous Squamous Cell Carcinoma in Situ, with 1 trials.
Top-decile sponsor footprint
Sirnaomics ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
11 total, page 1 of 1
Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects
NCT05844293
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
NCT05037149
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC
NCT05421013
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty
NCT05422378
A Study of STP707 Administered by IV in Healthy Subjects
NCT05309915
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC
NCT04844983
A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence
NCT04844840
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
NCT04676633
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
NCT04669808
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
NCT04293679
A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar
NCT02956317
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Sirnaomics pipeline
1 recruiting of 11 indexed (9% open); 9 completed (82%).
Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Cutaneous Squamous Cell Carcinoma in Situ (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sirnaomics: open-pipeline peers nationwide
Peers matched on 11 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Sirnaomics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 trials (± recruiting share)
- Aderans Research Institute · 11 trials · 0% recruiting
- Aegerion Pharmaceuticals · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Alkermes · 9% recruiting · 66 trials
- DBV Technologies · 9% recruiting · 11 trials
- Florida Gulf Coast University · 9% recruiting · 11 trials
- Genfit · 9% recruiting · 11 trials
Related
What to do with this Sirnaomics page
11 registered trials is a research-attention snapshot, not an endorsement of Sirnaomics or any single study.
- 1 of Sirnaomics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cutaneous Squamous Cell Carcinoma in Situ is the condition Sirnaomics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cutaneous Squamous Cell Carcinoma in Situ trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sirnaomics pipeline card: 11 registered trials from official public datasets.Report a data error.